Shopping Cart
Remove All
Your shopping cart is currently empty
Otlertuzumab
😃Good
Catalog No. T77358Cas No. 1372645-37-8
Alias TRU-016
Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinaemia (WM).
Otlertuzumab
Otlertuzumab
😃Good
Catalog No. T77358Alias TRU-016Cas No. 1372645-37-8
Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinaemia (WM).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $215 | - | In Stock | |
| 5 mg | $560 | - | In Stock | |
| 10 mg | $896 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:98.5% (SDS-PAGE); 99.6% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinaemia (WM). |
| In vitro | Otlertuzumab (TRU-016), being developed by Trubion Pharmaceuticals Inc and Facet Biotech Corp, is an intravenously administered anti-CD37 IgG fusion protein for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), as well as autoimmune and inflammatory diseases. |
| Synonyms | TRU-016 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TSPAN26/CD37 |
| Molecular Weight | 144.65 kDa |
| Cas No. | 1372645-37-8 |
| Isotype | IgG1 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Otlertuzumab | purchase Otlertuzumab | Otlertuzumab cost | order Otlertuzumab | Otlertuzumab in vitro | Otlertuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.